王捷

• 1:江苏省人民医院
• 2:哥伦比亚大学医学院

摘要(Abstract)：

<正>欧洲高血压学会(European Society of Hypertension,ESH)最近新发布的立场文件~([1]),与其在2018年发布的高血压管理指南~([2])中对经导管去肾交感神经术(renal denervation,RDN)最大的不同是:3年前对RDN作为治疗高血压的常规疗法,尚抱着怀疑和不推荐的态度,而今已明确地表态,RDN可以作为临床上控制血压的三种方法之一(其他两种方法是生活方式改善和药物治疗)。这一态度明确而坚定。基于这一总的原则,立场文件详细地阐述和解释了支持这一立场的基础研究/循证医学证据和这一疗法目前所面临的主要问题和挑战,

关键词(KeyWords)： 经导管去肾交感神经术;高血压;主要不良心血管事件

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 王捷

参考文献(References)：

• [1] Schmieder RE, Mahfoud F, Mancia G, et al. European Society of Hypertension position paper on renal denervation 2021.J Hypertens,2021, 39(9):1733-1741.
• [2] Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension:The task force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension.J Hypertens, 2018,36(10):1953-2041.
• [3] Kandzari DE, Kario K, Mahfoud F, et al. The SPYRAL HTN global clinical trial program:rationale and design for studies of renal denervation in the absence(SPYRAL HTN OFF-MED)and presence(SPYRAL HTN ON-MED)of antihypertensive medications. Am Heart J,2016,171(1):82-91.
• [4] James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults report from the panel members appointed to the eighth Joint National Committee(JNC 8). J Am Med Assoc,2014, 311(5):507-520.
• [5] Townsend RR, Mahfoud F, Kandzari DE, et al. Catheterbased renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications(SPYRAL HTNOFF MED):a randomised, sham-controlled, proof-ofconcept trial. Lancet,2017,390(10108):2160-2170.
• [6] Kandzari DE, B?hm M, Mahfoud F, et al. Ef fect of renal denervation on blood pressure in the presence of antihypertensive drugs:6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet,2018, 391(10137):2346-2355.
• [7] B?hm M, Kario K, Kandzari DE, et al. E fficacy of catheterbased renal denervation in the absence of antihypertensive medications(SPYRAL HTN-OFF MED pivotal):a multicentre, randomised, sham-controlled trial. Lancet,2020, 395(10234):1444-1451.
• [8] Azizi M, Schmieder RE, Mahfoud F, et al. Endovascular ultrasound renal denervation to treat hypertension(RADIANCEHTN SOLO):a multicentre, international, single-blind,randomised, sham-controlled trial. Lancet,2018,391(10137):2335-2345.
• [9] Azizi M,Sanghvi K,Saxena M,et al. Ultrasound renal denervation for hypertension resistant to a triple medication pill(RADIANCEHTN TRIO):a randomised, multicentre, single-blind, shamcontrolled trial. Lancet,2021,397(10293):2476-2486.
• [10]国家医疗器械技术审评中心.肾动脉射频消融产品临床试验考虑因素.
• [11] Kandzari DE,Townsend RR,Bakris G,et al. Renal denervation in hypertension patients:Proceedings from an expert consensus roundtable cosponsored by SCAI and NKF. Catheter Cardio Inte,2021,98(3):416-426.
• [12] Wang Y,Wang JW,Wang Y,et al. Monitoring antihypertensive medication adherence by LC-MS/MS:method establishment and clinical application. J Cardiovasc Pharmacol,2021, 78(4):581-596.
• [13] Mahfoud F, Mancia G, Schmieder R, et al. Renal denervation in high-risk patients with hypertension. J Am Coll Cardiol,2020,75(23):2879-2888.
• [14] Kandzari ED,Hickey GL,Pocock SJ,et al. Prioritised endpoints for device-based hypertension trials:the win ratio methodology,Euro Intervention,2021,16(18):e1496-e1502.
• [15] Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1.Overview, meta-analyses, and meta-regression analyses of randomized trials. J Hypertens,2014, 32(12):2285-2295.
• [16] Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death:a systematic review and meta-analysis. Lancet, 2016, 387(10022):957-967.
• [17] Blood Pressure Lowering Treatment Trialists Collaboration.Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure:an individual participant-level data meta-analysis. Lancet,2021,397(10285):1625-1636.
• [18] Townsend RR, Sobotka PA. Catheter-based renal denervation for hypertension. Curr Hypertens Rep,2018,20(11):93.
• [19] Fengler K,Rommel KP,Blazek S,et al. A three-arm randomized trial of different renal denervation devices and techniques in patients with resistant hypertension(RADIOSOUND-HTN).Circulation,2019,139(5):590-600.
• [20] Fudim M, Sobotka AA, Yin YH, et al. Selective vs. global renal denervation:a case for less is more. Curr Hypertens Rep,2018,20(5):37.
• [21] Liu H, Chen W, Lai Y, et al. Selective renal denervation guided by renal nerve Stimulation in canine:a method for identification of optimal ablation target. Hypertension,2019,74(3):536-545.
• [22] Chinushi M, Izumi D, Iijima K, et al. Blood pressure and autonomic responses to electrical stimulation of the renal arterial nerves before and after ablation of the renal artery. Hypertension,2013, 61(2):450-456.
• [23] de Jong MR,Adiyaman A,Gal P,et al. Renal nerve stimulation–induced blood pressure changes predict ambulatory blood pressure response after renal denervation. Hypertension,2016, 68(3):707-714.
• [24] van Amsterdam WA, Blankestijn PJ, Goldschmeding R, et al. The morphological substrate for renal denervation:Nerve distribution patterns and parasympathetic nerves. A post-mortem histological study. Ann Anat,2016, 204:71-79.
• [25] Schmieder RE, Kandzari DE, Wang TD, et al. Dif ferences in patient and physician perspectives on pharmaceutical therapy and renal denervation for the management of hypertension. J Hypertension,2021, 39(1):162-168.